Ascofer

Quick links to important sections

Ascofer

Method of action: Antianemic

Treatment option: Pregnancy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ascofer

What is Ascofer?

Ascofer is an oral iron supplement used to address iron deficiency in the body. It contains iron in the form of iron(II) gluconate, which is a chemical compound that provides a source of elemental iron necessary for the production of hemoglobin and the proper functioning of various metabolic processes.

Composition and Form

The primary active component of Ascofer is ferrous gluconate. This specific form of iron is often selected for its solubility and its ability to be absorbed by the gastrointestinal tract. By providing a supplemental source of iron, it helps to replenish the body's iron stores when dietary intake is insufficient or when there is an increased physiological demand.

Role of Iron in the Body

Iron is a vital mineral that plays a central role in human health. Its primary functions include:

  • Hemoglobin Production: Iron is a core component of hemoglobin, the protein in red blood cells responsible for transporting oxygen from the lungs to the rest of the body.
  • Myoglobin Support: It is essential for myoglobin, a protein that provides oxygen to muscles.
  • Enzymatic Functions: Iron serves as a cofactor for several enzymes involved in energy metabolism and DNA synthesis.

Indications

Ascofer is utilized in the management of iron deficiency states. This includes the treatment of iron deficiency anemia, a condition where the lack of iron leads to a reduced number of healthy red blood cells. It is also used as a preventive measure in individuals who are at a higher risk of developing a deficiency, ensuring that iron levels remain within a healthy physiological range.

What side effects are possible with Ascofer?

Possible Side Effects and Safety Information

The safety profile for Ascofer (Ferrous Gluconate) outlines officially classified adverse reactions and high-level safety constraints as documented in regulatory sources.

Adverse Reaction Classification

The most frequently documented adverse reactions are associated with the Gastrointestinal Disorders system-organ class. These effects, such as nausea, vomiting, constipation, diarrhea, stomach pain, and heartburn, are generally classified as Common in regulatory labeling. A frequent, expected effect is the darkening or black discoloration of the stools.

Time-related safety notes indicate that these common gastrointestinal symptoms may often be temporary and potentially lessen as the body adjusts to the oral iron treatment.

Serious Safety Constraints and Warnings

Official regulatory documents emphasize a critical risk regarding accidental overdose of iron-containing products. This risk is cited as a leading cause of fatal poisoning in children under six years of age and is subject to mandatory safety warnings. Serious adverse reactions, often associated with acute toxicity, include severe gastrointestinal events such as gastrointestinal necrosis or perforation.

Population-Specific Restrictions

Ferrous Gluconate is subject to formal contraindications that define specific populations who should not use the medicine. It is restricted for individuals with pre-existing iron overload disorders, such as hemochromatosis or hemosiderosis, and is not intended for use in anemias that are not caused by iron deficiency, such as hemolytic anemia. Caution is also advised in patients with certain active gastrointestinal diseases.

Overdose and Emergency Response

The official regulatory profile for iron product overdose, such as Ascofer (Ferrous Gluconate), defines a rapid progression of severe symptoms and a critical need for immediate medical intervention. Accidental overdose of iron-containing products is designated as a leading cause of fatal poisoning in children younger than six years; therefore, strict adherence to the warning to keep this product out of reach of children is mandated.

Initial documented manifestations of overdose primarily affect the gastrointestinal tract, presenting as vomiting, diarrhea, and severe abdominal pain, potentially including vomiting blood or bloody stools. If left untreated, these acute symptoms may progress to systemic collapse marked by hypotension (low blood pressure), tachycardia (rapid heart rate), and severe CNS effects such as seizures and coma. Life-threatening outcomes documented in the label include shock, hepatic necrosis (liver failure), and metabolic acidosis.

Official guidance states that if an overdose is suspected, an individual must call a doctor or poison control center immediately and seek emergency medical attention. Immediate medical help is required when an individual has collapsed, has trouble breathing, or cannot be awakened. Hospital management is necessary, which may involve specialized procedures like whole-bowel irrigation, continuous monitoring of vital signs, and the administration of the specific iron chelating agent Deferoxamine.

Therapeutic Uses of Ascofer

What Ascofer Treats: Main Uses and Benefits

Ascofer, which contains Ferrous Gluconate, is commonly used in the management of a low blood level of iron, generally applied for Iron Deficiency Anemia (IDA). It is relevant across domains where additional symptomatic support is needed to address the resulting symptoms related to systemic imbalance, as iron products are essential in the management of this deficit.


Easing Symptoms Related to Systemic Imbalance

The medication is commonly used to help with symptom clusters that may become intense or disruptive, such as profound fatigue, physical weakness, and issues like pallor or dizziness, which often interfere with daily functioning. The primary therapeutic benefit is to address symptoms that create noticeable physiological strain. The medication supports the patient during these difficult episodes by helping to improve day-to-day comfort during symptomatic periods.

Quick Fact: Relevant for Managing Pervasive Fatigue

Indications often involve its use during pregnancy and lactation, for those with heavy menstrual bleeding, or in cases of chronic iron loss or impaired absorption. Supportive relief may assist when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.


Support During High-Demand Clinical Scenarios

The medication is considered relevant in contexts marked by increased physiological stress, commonly used in conditions marked by increased physiological stress where the systemic burden is elevated. This supportive benefit contributes to easing the overall symptom load associated with iron deficiency and may assist with maintaining functional stability for individuals in these phases.

Regulatory References

  1. NIH MedlinePlus overview of Iron Supplements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ascofer

Official regulatory documentation defines eligibility for Ascofer (Ferrous Gluconate) based primarily on iron status, age, and existing comorbidities.


Populations for whom use is Contraindicated

Classification Population / Condition
Absolute Prohibition Iron Overload Disorders (e.g., Hemochromatosis, Hemosiderosis)
Absolute Prohibition Hemolytic Anemia or other anemias not caused by iron deficiency
Absolute Prohibition Children under 6 years of age (due to high risk of fatal poisoning)

Restricted and Conditional Use

Individuals with an active peptic ulcer, Ulcerative Colitis, or other severe gastrointestinal diseases are generally restricted from use or require caution. Use is also advised with caution in older adults, as anemia in this group may not be due to simple iron deficiency. Furthermore, use in premature infants is not recommended until vitamin E stores are replenished.


Pregnancy and Lactation Eligibility

Use of Ascofer is generally acceptable for both pregnant women and lactating women for the prevention and treatment of iron deficiency, which is commonly recommended by public health organizations. Use in these populations is permissible when a deficiency is documented.


Connection to the overall eligibility profile Regulatory documents establish clear contraindications that prioritize patient safety by prohibiting use in cases of iron overload or high-risk populations, specifically young children. Eligibility is otherwise permitted for populations with a confirmed iron deficiency who do not possess any specified absolute counter-conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ascofer (Ferrous Gluconate) defines clinically significant interactions primarily based on two mechanisms: pharmacokinetic interference with absorption and the risk of additive toxicity.


Interaction Scope

Category Documented Regulatory Entities
Medicinal Products Quinolone and Tetracycline Antibiotics, Thyroid Products (Levothyroxine), Bisphosphonates, Dopaminergic Agents (Carbidopa/Levodopa), Antacids, Proton Pump Inhibitors (PPIs), Chelating Agents (Deferiprone).
Mechanistic Basis Pharmacokinetic interaction (reduced absorption due to chelation or altered gastric pH); Pharmacodynamic interaction (additive toxicity).

Interaction Restrictions and Timing Rules

  • Timing Separation Required: Mandatory separation periods are required for numerous co-administered medicines to mitigate the risk of reduced drug exposure. Examples include administering Quinolone Antibiotics at least two hours before or six hours after Ascofer, and separating Levothyroxine administration by at least four hours. Tetracycline Antibiotics must also be separated by a minimum of two hours.
  • Restricted Combinations: Co-administration with Dimercaprol is restricted due to the documented potential for increased nephrotoxicity. Simultaneous use with Parenteral Iron Preparations is restricted due to the risk of iron overload.
  • Food and Supplements: Consumption of Dairy Products, Coffee, and Tea is documented to reduce the absorption of Ferrous Gluconate. Antacids and pH-altering agents also officially decrease Ascofer absorption.

Connection to the Overall Interaction Profile

Regulatory documents structure the product's interaction profile around a prominent absorption constraint, which affects the exposure of numerous co-administered drugs and requires mandatory time spacing. The profile also formally documents a specific pharmacodynamic risk when combined with Dimercaprol.

Mechanism of Action

Ascofer, a preparation containing ferrous gluconate, functions by increasing systemic iron levels. The iron(II) cation ( Fe^2+) is the principal biologically active component. Following absorption, primarily in the duodenum, the Fe^2+ is oxidized to Fe^3+ and binds to the transport protein transferrin in the plasma. This Fe^3+-transferrin complex is trafficked to target tissues, notably the bone marrow, where it interacts with the transferrin receptor 1 ( TfR1) on the surface of developing erythroblasts.

Binding to TfR1 initiates receptor-mediated endocytosis, internalizing the complex into an endosome. Acidification within the endosome liberates the iron, which is then transported into the cell cytoplasm via the divalent metal transporter 1 ( DMT1). Intracellularly, iron enters the labile iron pool, where it is utilized as an essential cofactor. The iron is subsequently incorporated into the protoporphyrin ring to synthesize the heme component of hemoglobin. This process modulates the rate of effective erythropoiesis, resulting in an increased total circulating Fe^2+ and subsequent functional protein mass in the systemic circulation.

Dosage and Administration Information

How to Use Ascofer (Ferrous Gluconate + Ascorbic Acid)

Ascofer must be administered strictly according to official labeling, which outlines the proper procedures for dosing and administration. This guide details the method of use without discussing indications, side effects, or drug interactions.

Administration and Dosing Protocol

Scope of Use Official Instructions
Route of Administration Oral administration only.
Dosage Form Coated tablets (swallow whole).
Timing in Relation to Meals Take tablets during or immediately after a meal.
Adult Therapeutic Dose Standard regimen is typically 2 tablets, three times daily.
Children's Dosing Dosing is determined by body weight, calculated as 4 mg to 6 mg of elemental iron per kg of body weight daily, divided into multiple doses.

Frequency and Course Duration

Ascofer is intended for daily administration with doses divided over the course of the day.

Duration of Therapy: Treatment is designed to be regular and long-term, often extending for a minimum of three months after blood parameters normalize to ensure the complete repletion of iron stores. The precise course duration must be determined by a healthcare professional based on laboratory findings.

Special Instructions

  • Tablet Integrity: Coated tablets must be swallowed whole with water. They should not be crushed, chewed, or dissolved, as this may affect absorption and gastric tolerance.
  • Dose Limits: Dosage must be strictly adhered to; exceeding recommended doses, particularly in children, carries a risk of iron intoxication.
  • Pregnancy/Lactation: Dosing adjustments for pregnant or breastfeeding individuals should only be made following specific laboratory testing to determine the exact iron requirement.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ascofer

Research Evidence for Iron Deficiency Anemia (IDA) Treatment

The research on Ascofer, or its active ingredient Ferrous Gluconate, has primarily focused on studies designed to evaluate the use of Ascofer in the context of Iron Deficiency Anemia (IDA). This evidence is built from various high-level study designs, including Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews.

Researchers examined whether Ferrous Gluconate was associated with changes in essential blood markers that define iron status, focusing on Hemoglobin (Hb) concentration and Serum Ferritin levels. In these trials, studies documented changes in both Hb and ferritin levels over treatment periods lasting between three and six months. Studies also monitored outcomes related to systemic imbalance, such as patient-reported fatigue, reporting that symptoms evolved during the observed treatment intervals.

What is known comes mostly from short-term data. Long-term effects are not fully established, and it can be challenging to isolate data specifically for Ferrous Gluconate alone, as many systematic reviews combine findings for various oral iron salts. The evidence quality varies across studies, and the results apply only to the populations studied.


Evidence for Prophylactic (Preventive) Use

Research has also explored the role of iron supplementation in prophylactic settings, aiming to study the prevention of the development of iron deficiency. This work largely relies on RCTs examining routine supplementation regimens in at-risk populations.

The trials were studied for their ability to prevent the incidence of maternal anemia (measured by low Hb) in pregnant women. These studies documented lower measurements in the incidence of maternal anemia in those who received the supplement compared to non-supplemented groups. However, the findings were mixed regarding any association with non-anemia-related birth outcomes, and certainty remains low in these areas.

A key point of research limitation is the inconsistency in official clinical guidelines regarding routine iron supplementation in pregnant populations who are not yet diagnosed with iron deficiency.

Key Studies & References

  1. Oral Iron for Anemia: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines
  2. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women (2012)
  3. Antenatal iron supplementation (WHO)
  4. Tolerability of different oral iron supplements: a systematic review (Cancelo-Hidalgo et al.)
  5. ATC code B03AA03 (ferrous gluconate) - WHO Collaborating Centre for Drug Statistics Methodology

Frequently Asked Questions (FAQ)

Common questions about Ascofer (FAQ)

Q: What are the signs that Ascofer is actually working?

Ascofer works by replenishing the body’s iron stores, which are necessary for oxygen transport. While the full therapeutic effect is monitored by changes in blood markers like Hemoglobin and Ferritin, official studies have noted that patient-reported fatigue tends to improve during treatment intervals.

Q: Does Ascofer work differently for men and women?

Official guidance indicates that iron requirements, known as the Recommended Daily Intake (RDI), differ between adult men and non-pregnant women. The therapeutic need for supplementation and the specific dosing regimen are determined based on these differing individual requirements.

Q: Can Ascofer affect the results of blood tests?

Official information indicates that the therapeutic purpose of Ascofer is to alter certain blood parameters, specifically by raising levels of Hemoglobin and Ferritin. For this reason, official monitoring protocols rely on regular blood tests to determine the effectiveness and duration of the therapy.

Q: Is a higher dose of Ascofer related to greater effect?

The standard therapeutic dosing is designed to achieve the necessary effect while maintaining a high standard of patient safety. Regulatory warnings emphasize the importance of adhering to the prescribed dose, as exceeding recommended levels carries a formal risk of serious complications, including iron intoxication.

Q: What is the difference between Ascofer and other drugs in the same class?

Ascofer contains Ferrous Gluconate, which is an oral iron salt generally associated with favorable absorption compared to other ferric salts. The formulation often strategically includes Ascorbic Acid (Vitamin C), which is noted in official sources to help keep the iron in its most absorbable form.

Q: How long is Ascofer approved for use?

Treatment is typically designed to be a regular and long-term course, often continuing for a minimum of several months after laboratory blood markers return to normal. Regulatory monographs advise that continuous administration of oral iron for periods exceeding six months should generally be avoided unless a physician identifies a clear, ongoing cause like chronic blood loss.

Q: Are there different versions or strengths of Ascofer?

The product is commercially available in various formulations, such as coated tablets or capsules, across different markets. These formulations may contain different specific strengths of Ferrous Gluconate, providing varying amounts of the active ingredient (elemental iron).

Q: Is the research evidence for Ascofer strong?

Research has examined the efficacy of oral iron preparations in improving laboratory markers of iron deficiency, such as Hemoglobin and Ferritin levels. However, official evidence reviews indicate that data related to some broader clinical outcomes, such as non-anemia-related birth outcomes, are currently limited.

Q: Does Ascofer require any special monitoring while taking it?

Official treatment protocols indicate that the duration of use is determined by a healthcare professional and relies on regular laboratory monitoring of specific blood count tests.

Q: Are there any known long-term side effects listed for Ascofer?

Regulatory documents caution that long-term excessive use is associated with a risk of iron accumulation, which may lead to adverse effects, especially for individuals with existing conditions like liver dysfunction. For this reason, use is generally limited to the time required to correct the iron deficiency.

Q: Can I take Ascofer if I have a known allergy to other medications?

Official product information states that the medicine is formally restricted for anyone with a known hypersensitivity or allergy to its active substance (Ferrous Gluconate) or any of the inactive ingredients (excipients). Information regarding allergies to unrelated medications is not specifically detailed in the regulatory label.

Q: Is Ascofer the same thing as its generic name?

The active substance in Ascofer is Ferrous Gluconate. This iron salt is the common chemical name, often referred to as the generic name, and is the basis for all branded and unbranded formulations of this particular iron salt.

Q: Does Ascofer interact with over-the-counter pain relievers?

Official documentation broadly indicates that the iron component may interact with various substances, including certain over-the-counter medicines, vitamins, and herbal products. Regulatory documents advise that a healthcare provider should be informed of all medicines and supplements currently being used.

Q: Do I need a prescription to get Ascofer?

In some countries, formulations of Ferrous Gluconate are available without a prescription and are marketed as Dietary Supplements. However, the higher-strength preparations typically used for treating diagnosed iron deficiency may require a prescription in order to be dispensed.

Q: Can I take herbal supplements at the same time as Ascofer?

Regulatory documentation cautions that the iron component of the product may interact with various herbal products. Regulatory documentation advises that a healthcare provider should be informed of all herbal products and supplements being used to assess for potential interaction risks.

Q: Is it possible to be allergic to Ascofer?

Official regulatory documents list hypersensitivity (an allergic reaction) to the active substance (Ferrous Gluconate) or any of the inactive ingredients (excipients) as a formal contraindication for use.

Q: Does alcohol interfere with Ascofer?

Interaction monographs document that there is an interaction between the active substance, Ferrous Gluconate, and alcohol consumption. This documented interaction is generally classified as moderate, and regulatory information advises seeking guidance from a healthcare provider regarding alcohol consumption.

Q: Is it safe to take Ascofer if I have kidney problems?

Official product safety information indicates that caution should be taken when using this medicinal product in the case of pre-existing kidney disease or impaired kidney function.

How should Ascofer be stored and disposed of?

How to Store and Dispose of Ascofer?

Storing and disposing of Ascofer (Ferrous Gluconate) must strictly follow official regulatory guidelines to ensure product stability and patient safety.

Official Storage Requirements

The medication should be stored at USP Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F). The container must be kept tightly closed and protected away from light and moisture, meaning storage in high-humidity areas like a bathroom is prohibited. The medicine must be kept out of the sight and reach of children due to the severe risk of accidental iron overdose, and the container must have a child-resistant closure.

Official Disposal Rules

When disposing of unused or expired Ascofer, do not flush the medication down the toilet or pour it down a drain. Discard the product using a medicine take-back program or follow specific local requirements for pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ascofer found in:

A-Z Index: